Purpose. A prospective randomized trial in small-cell lung cancer (SCLC) was performed to determine if intensification of the platinum dose by giving cisplatin and carboplatin in combination to patients with SCLC yields higher response rates and survival, than carboplatin alone in a combination chemotherapy regimen.
Introduction
Small-cell lung cancer accounts for about 25% of all cases oflung cancer [1] . Unfortunately, due to its aggressive nature and rapid rate of dissemination, SCLC is usually advanced at diagnosis. During the 1970s, the development of multidrug combinations resulted in a significant improvement in the treatment response and survival in patients with SCLC with an increase in overall response rates to 70%-90% and complete response rates to 30%-50%. The median survival reached 14 months in patients with limited disease (LD), and 10 months in patients with extensive disease (ED) [2] . The integration of epipodophyllotoxin derivatives (etoposide or teniposide) in existing chemotherapy regimens was associated with a modest but significant improvement in survival [3, 4] . Although SCLC initially responds well to chemotherapy, relapse occur in the majority of patients within two years [5] , indicating that selection of and overgrowth by drug-resistant cells is the major culprit for treatment failure during cancer chemotherapy. To circumvent this problem, a number of trials have applied alternating non-cross-resistant chemotherapy, but the majority of the studies have not shown a significant benefit to this approach [6] .
Although multiple regimens yield similar survival results, the current state-of-the-art management for SCLC remains platin-based combination chemotherapy alone in extensive disease and with radiotherapy in limited disease stage [6] . The role of etoposide and cisplatin in the management of patients with SCLC has recently been verified in two published meta-analyses [7, 8] . Nevertheless, as the overall cure rate remains less than 10% an improvement of the treatment is warranted.
In order to avoid prehydration and nephrotoxicity, several studies have evaluated the use of carboplatin instead of cisplatin, all proving that carboplatin can be substituted for cisplatin without apparent loss of therapeutic efficacy [9] [10] [11] [12] [13] . In our own trial no significant difference were observed in tumor response or survival between the cisplatin-containing regimen and the carboplatin-containing regimen, but we noticed less neuro-and nephrotoxicity in the carboplatin-containing treatment regime [13] .
One approach to overcome drug resistence has been dose escalation, which has not yet proved to be beneficial in the management of SCLC, regardless of stage. At least seven randomized trials have evaluated dose intensity in SCLC mostly in patients with extensive disease [14] [15] [16] [17] [18] [19] [20] . The planned differences in dose intensity between the high-and low-dose arms have ranged between 1.2-and two-fold, but the differences in actually delivered doses were less [21] . Three of the seven randomized trials showed a modest advantage for the higher dose therapy. However, two of these three studies gave less than standard dose therapy in the reference arm [21] . The addition of colony-stimulating factors (G-CSF, GM-CSF) in enable a higher dose delivery has not proved advantageous in some studies [22, 23] , while survival benefit has been supported by others [24] . Among the many high-dose regimens, however, none has looked on intensification of the platinum component by combined administration of cis-and carboplatin, taking advantage of different toxicity profiles for the two agents.
The aim of the present study was, therefore, to investigate, whether or not an increased dose of platinum, by combination of cisplatin and carboplatin is more active than combination chemotherapy containing only one platinum compound (carboplatin) with the drugs used in combination chemotherapy. The design of the protocol was based on our previous randomized study demonstrating the best treatment outcome in our institutions by using a combination of cisplatin or carboplatin combined with teniposid and vincristine as induction chemotherapy followed by an alternating multichemotherapy regimen including cyclophosphamide and 4-epirubicin [13] .
Patients and methods

Patient selection
From September 1992 to October 1997, 280 patients with newly diagnosed SCLC were entered into this trial at one of six institutions (The Finsen Center, Herlev University Hospital, Bispebjerg Hospital, Hilleroed Hospital. Roskilde Hospital, and Nfestved Hospital). The protocol was approved by the local ethical committees.
Eligibility criteria were the following: 1) histologically proven SCLC, 2) no prior chemo-or radiotherapy, 3) age < 70 years, 4) no previous or concomitant malignancy other than adequately treated squamous cell or basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix, 5) normal renal function based on 5l Cr-EDTA clearance, and 6) informed signed consent. All performance status (PS) categories were accepted PS was scored according to the WHO criteria [25] .
Pretreatment staging included physical examination with registration of height, weight and performance status, blood chemistry including complete blood cell and platelet counts, plasma electrolytes, creatinine, liver function tests (aspartate aminotransferase, lactate dehydrogenase and alkaline phosphatase), urinanalysis, 5l Cr-EDTAclearance and ECG Staging procedures included bronchoscopy, chest X-ray, abdominal ultrasound scan, and bilateral iliac crest bone marrow biopsies and aspirates. Brain CT-scan and other diagnostic procedures were only performed when clinically indicated.
Limited disease (LD) was defined as tumor limited to one hemithorax, mediastinal and/or supraclavicular lymph nodes. A pleural effusion without tumor cells was accepted in LD Extensive disease (ED) was defined as tumor present outside these regions.
Therapy
Eligible patients were randomized to one of two treatments. The randomization was based on a closed envelope system. PTe-randomlzation stratification considered treatment center, stage of disease, LDH and performance status. Regimen B also consisted a total of six courses, which were identical to regimen A, except for the exclusion of cisplatin.
Radiotherapy was only given for palliation of progressive disease, such as brain metastases, superior vena cava syndrome, and bone metastases.
Dose modifications were made based on hematologic and renal toxicity. A new treatment cycle was delayed one week if the WBC <3000/ml or the platelet count <75,000/ml. Following leukopenic fever or nadir platelet counts ^50,000/ml the doses of chemotherapy were reduced 25%, except for cisplatin and vincnstine. Cisplatin was reduced if the 5l Cr-EDTA-clearance fell to subnormal values, and vincristine was reduced or discontinued after gTade 3-4 neurotoxicity (WHO). The dose was modified if any clinically neurotoxicity of the treatment (i.e., polyneuropathy or peroneus nerve dysfunction) was observed. If WBC nadir > 3000/ml and platelet nadir > 100,000/ml, doses of carboplatin and teniposide were intended to escalate to 133%.
Evaluation
Primary endpoint of the trial was overall survival in arm A compared to arm B. Secondary endpoints were response rates and duration in arm A as compared to arm B Another secondary endpoint was was a subgroup analysis of survival within each disease stage category comparing arm A to arm B. Response and toxicity were classified in accordance with the WHO criteria [25] , Duration of survival as well as response were counted from the day of randomization.
Blood chemistry and chest X-rays were repeated every four weeks. Patients were re-evaluated after three courses of chemotherapy and again after six courses Evaluation consisted of chest X-ray, bronchoscopy and all examinations that were abnormal at the pre treatment staging.
Patients with residual disease at the final re-evaluation could continue chemotherapy. At relapse most of the patients were offered phase II trials.
Statistical methods
The trial was dimensioned to 450 patients based on a hypothesis, that the double platinum regime would increase median survival from 12 to 16 months (33% improvement) which should be detectable with a power of 0.80 and a = 0.05. Accrual period was estimated to four years with 2 5 years follow-up. Interims analysis was not planned, but was undertaken after five years, when 280 patients had been accrued. There (49) 71 (51) 112 (80) 24 (17) 4 (3) 27 (19) 35 (25) 8 (6) 47(33) 117 (84) 17 (12) 6(4) 22 (16) 32 (23) 9(6) 38 (27) " No statistical significant difference in any of the parameters. P < 0.05. was no statistical difference in the overall survival (LD + ED) between the groups, and when application of data on a sequential model proved, that statistical significant difference would not occur by continued accrual to the stipulated 450 patients, the trial was concluded
The statistical software SPSS for Windows (version 9.0) was used for data handling and statistical analysis. Fisher's exact test or the chi square test was used for comparisons between the treatment groups of categorical variables such as response rates and two-year survival rates, while the non-parametric Mann-Whitney test was used when continuous variables such as age and nadir values were compared Survival analysis was based on the Kaplan-Meier model, using the log-rank test in testing for statistical significant differences Level of significance in all tests was P < 0.05, two sided.
Results
A total of 280 patients were included into the trial, 140 patients in arm A, and 140 patients in arm B. The prognostic variables are shown in Table 1 . There were no statistically significant differences observed between the two treatment arms related to gender, age, stage, LDH, performance status, bone-marrow-, liver-, brainand lymph node metastases. Ten patients did not complete the scheduled treatment due to other causes than death or progression: seven patients in arm A and three in arm B. The reasons were patient refusal (three and two patients, respectively) and grade 3-4 non-hematologic toxicity in four and one patient, respectively. These 10 patients were included in the survival analysis. 120 mg and 560 mg, respectively). None of the patients had dose escalation of teniposide or carboplatin. There were no differences between the cumulative doses of vincristine, cyclophosphamide and 4-epirubicine between the two arms.
Response
Response rates for the two treatment regimens are shown in Table 3 . Of the 280 patients, 270 patients were assessable for response. Of 136 patients in arm A, 98 patients (72%) had an objective response, as did 96 (72%) of 134 patients in arm B. The complete remission rates (CR) were 40% for arm A, and 34% for arm B (P = 0.31). In patients with limited disease, the CR was obtained in 36 patients (54%) of patients treated in arm A versus 27 patients (37%) in arm B (P = 0.044). Partial remission (PR) were obtained in 16 patients (24%) in arm A versus 24 patients (32%) in arm B. In extensive disease CR was obtained in 19 patients (28%) in arm A and in 18 patients (30%) in arm B (P = 0.85).
The median duration of response was 241 days in arm A and 239 days in arm B (P = 0.98, log-rank test). Median response duration in limited and extensive stage disease, respectively, were: 273 days vs. 268 days (P = 0.71) and 217 days vs. 225 days (P = 0.66).
Survival
Cumulative doses of carboplatin and teniposide were 5%-10% less in arm A compared to arm B ( Table 2) . The difference was statistically significant (P < 0.05). Patients in arm A received a median cumulative dose of cisplatin of 450 mg (the 10% and 90% percentiles were
The survival curves are shown in Figures 1-3 . There was no difference in the overall survival between arm A and B (P > 0.05) (Figure 1 ). Median survival time was 314 days in arm A and 294 days in arm B (P -0.42). For patients with limited disease, however, there was a statisti- and Chi-square tests were used comparing transfusions and leukopenic fever (P = 0.039, log-rank test) (Figure 2) . No difference in survival was observed for patient with extensive disease with an overall median survival for patients with extensive disease of 233 days, 232 days in arm A and 233 days in arm B (P = 0.29) (Figure 3 ). Long-term survival (>2 years) was observed in 5% and 4% of patients in arm A and arm B, respectively. In limited disease two-year survival was 8.3%, 11% in arm A versus 6% in arm B (P < 0.05). Only 1% of patients with extensive stage disease were alive after two years.
Toxicity
Early death (before day 29 from randomization) occurred in 25 patients, 18 patients (14 of whom had ED) in arm A and 7 patients in arm B (5 with ED) (P = 0.06). Neutropenic fever was proven as a cause of death in 16 of these patients, 12 in arm A (9 patients with ED) and 4 in arm B (3 patients with ED) (P = 0.049). The cause of death for the remainder 9 patients was progressive disease. Table 4 shows haematologic toxicity. Haemoglobin nadirs were 5%-10% lower in arm A compared to arm B, WBC nadirs were 10%-20% lower and platelet nadirs in arm A were three to four times below the level in arm B. More patients in arm A -compared to arm B -were hospitalised because of neutropenic fever and more patients received blood transfusions. All differences were statistically significant (Mann-Whitney test).
Grade 2-3 neurotoxicity was recorded in 14% of the patients in arm A vs. 11% of the patients in arm B (P -0.19) and grade 2-4 gastro-intestinal toxicity was observed in 20% of the patients in arm A while 14% of the patients in arm B had grade 2-3 toxicity (P = 0.049). None of the patients had their treatment discontinued because of decreasing kidney function, but EDTA-clearance was not requested at post-treatment revaluation so no specific data on changes in the kidney function are available.
Discussion
The present study was undertaken in order to see whether intensification of the platinum component in a combination chemotherapy regimen could improve the treatment results in patients with SCLC compared to combination therapy with carboplatin alone. The increased platinum treatment was done by combining cisplatin and carboplatin taking the advantage of the different toxicity profiles of the two drugs.
For patients with limited disease, the study demonstrated a modest, but statistically significant survival benefit and more patients surviving two-year in the 'high-dose' platinum arm, than in the carboplatin arm (11% vs. 6%). Furthermore, the 'high-dose' platinum arm gave a significantly higher complete remissions rate (54%) compared to the carboplatin arm (37%). For the patients with extensive disease, however, no difference was observed in the treatment results between the two treatment arms.
Most of the previous studies investigating dose intensification in treatment of SCLC have been performed in patients with extensive disease, and so far none have been able to prove any dramatic beneficial effect of dose intensification on survival, but considerably more side effects [21] . One study, however, demonstrated improved disease-free survival and overall survival for patients with limited small cell lung cancer by a moderate increase in the initial dose of cisplatin and cyclophosphamide [20] . It is difficult to compare one study with another; in the study by Arriagada et al. [20] the increase in the platinum component was based on an increase in the cisplatin dose from 80 mg to 100 mg pr. square meter, while the current study included a combination of cisplatin and carboplatin. Whether this treatment approach really is reflecting a biological phenomenon needs to be further investigated. The reasons for the treatment failure of the dose intensification approach in patients with extensive disease in the current study could be related to tumor heterogeneity, resulting in an overwhelming prevalence of resistant clones in large, metastatic tumor volumes in addition to a general poor tolerance to chemotherapy in patients with extensive stage disease [5, 26] .
Our study demonstrated that the combination of cisplatin and carboplatin with regard to hematologicand non-hematologic side effects was tolerable in most of the patients, but there were, however, more toxic deaths in the high-dose platinum arm, and the WBCnadir level was lower in the high dose platinum arm than in the carboplatin arm. The toxicity in the present study did not, however, differ significantly from our previous studies [27] . In contrast to many other institutions, due to the social health care system in Denmark, unselected patients are referred to the oncology centers. Most of the patients were enrolled in the clinical protocols as long as the entrance criterias were met. Thus, even if about 80% of the patients had a goood performance status in the current study, about 20% of the patients had PS >1.0, which might impair the tolerance of 'high-dose' chemotherapy. The combination of cisplatin and carboplatin has been evaluated in patients with NSCLC [28] [29] [30] [31] [32] [33] . However, except for the study by Klastersky et al. [28] , the studies are smaller phase II studies. It has been difficult to compare the studies because of different study populations and especially different treatment /dosage schedules. In general a significant hematologic toxicity have been reported by the use of combinations of platinum drugs [29] [30] [31] . Four randomized studies in patients with NSCLC have adressed the question of dose intensification of cisplatin, none of which have shown significant benefit on survival, but significantly more severe toxicity [28, [34] [35] [36] . We are not aware of similar randomized studies in patients with SCLC. Based on more recent data it is likely to believe, that the use of granulocyte colony-stimulating factors or haemopoietic cell support could reduce the haematologic toxicity with no or only minute beneficial influence on survival [37, 38] . The hemoglobin nadirs in arm A were 5%-10% lower than in arm B and significantly more patients needed blood transfusions, which indicates that supportive treatment with epoetin alpha could be an appropriate option if cisplus carboplatin combination regimes are studied in future trials [39] . There were more patients experiencing grade 2-3 neuropathia in arm A compared to arm B in this trial, but the difference was not statistically significant. Considering, however, that the figures only were 14% and 11%, respectively, some degree of underreporting could be suspected. Neurotoxicity included five patients with tinitus in the high-dose platinum arm.
In the present study the dosage of carboplatin was based on area under the curve (AUC) calculations. The background for that was the correlation of toxicity to the AUC reported by Calvert et al. [40, 41] . However, it can be debated, whether a carboplatin dose of AUC = 4 as used in current study has been the most optimal dose of this drug. In several trials a higher dose of carboplatin have been used [42] . However, the WBC nadir in the present study was 0.9 (median value) in patients with extensive disease, which seems to be reasonable, but somewhat higher in limited disease (2.1), reflecting the difficulties in investigating treatment principles in patients representing all stages of the disease.
In the present study teniposide was used instead of etoposide. The reason for that is historical. When the trial was planned, we had just demonstrated, that the two agents lead to similar outcomes when used as single agent treatment of SCLC patients [43] .
The overall survival time for the whole population was quite disappointing in the present study, especially for the limited stage disease patients. At the time of initiating the current study thoracic irradiation and prophylactic cranial irradiation was debated, but not established as part of the standard treatment program for patients with limited disease SCLC. Therefore, none of the limited disease patients in the current protocol had thoracic irradiation. Later on, the documentation for improved treatment results with the combined modalities have been obtained based on meta-analyses [44] [45] [46] .
The present study demonstrated a difference in the treatment outcome restricted to patients with limited disease, with a moderate better survival and almost a doubling of the number of long-term survivors in the high-dose platinum arm. This might support the concept of intensifying the chemotherapy in this group of patients in the combined modality treatment program. More recently results from other groups have also been able to demonstrate improved treatment results with chemotherapy intensification [24] . For patients with extensive disease, however, the present study has demonstrated, that normal dose platinum (carboplatin) is as good as high-dose platinum treatment in terms of treatment outcome and giving a more tolerable toxicity profile. The current results do not support the idea that aggressive therapy may achieve results that are better than those obtained by less aggressive approaches for patients with extensive stage SCLC, despite more severe toxicity [47] . Our findings for patients with extensive stage SCLC was similar as reported by Urban et al. [48] , and the treatment of this group of patients today have to be considered mainly with the goal of palliation in contrast to the patients with limited disease.
